Insulin efsitora alfa
| Clinical data | |
|---|---|
| Other names | LY3209590; LY-3209590 |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Insulin efsitora alfa (LY3209590) is an insulin analog developed by Eli Lilly for the treatment of diabetes. Its glycemic control and safety were found similar to insulin degludec in a phase II trial.[1][2][3]
Society and culture
Legal status
In June 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Onswik, intended for the treatment of type 2 diabetes.[4] The applicant for this medicinal product is Eli Lilly Nederland B.V.[4]
Names
Insulin efsitora alfa is the international nonproprietary name.[5]
Research
A systematic review and metanalysis of insulin efsitora alfa, published in 2024, found that it may be useful in the management of type 1 and type 2 diabetes.[6]
References
- ↑ Heise T, Chien J, Beals JM, Benson C, Klein O, Moyers JS, et al. (2023). "Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes". Diabetes, Obesity and Metabolism. 25 (4): 1080–1090. doi:10.1111/dom.14956. PMID 36541037. S2CID 255034380.
- ↑ Moyers JS, Hansen RJ, Day JW, Dickinson CD, Zhang C, Ruan X, et al. (2022). "Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein". Journal of Pharmacology and Experimental Therapeutics. 382 (3): 346–355. doi:10.1124/jpet.122.001105. PMID 35840338.
- ↑ Kazda CM, Bue-Valleskey JM, Chien J, Zhang Q, Chigutsa E, Landschulz W, et al. (2023). "Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes". Diabetes Care. 46 (5): 1052–1059. doi:10.2337/dc22-2395. PMC 10154655. PMID 36920867.
- 1 2 "Onswik | European Medicines Agency (EMA)". www.ema.europa.eu. 26 June 2026.
- ↑ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information. 34 (3). hdl:10665/340680.
- ↑ Dutta D, Nagendra L, Kumar M, Kamrul-Hasan AB, Bhattacharya S (December 2024). "Optimal use of once-weekly basal insulin efsitora alfa in type 1 and type 2 diabetes: A systematic review and meta-analysis". Endocrine Practice. doi:10.1016/j.eprac.2024.12.013. PMID 39710291.